Year: 2018
Type: editorial
Abstract: Atezolizumab is a humanized IgG1 monoclonal antibody targeting programmed cell death-ligand 1 (PD-L1). Interactions between programmed cell death protein-1 (PD-1), expressed on T cells, and PD-L1 o...
Authors: Jason M. Redman, Ravi A. Madan
Institutions: National Institutes of Health, National Cancer Institute
Language: English
Subfield: Oncology
Field: Medicine
Domain: Health Sciences
Open Access status: bronze
OpenAlex ID: W2806033608